Home Your basket
• Progressive cochleo-vesti...
   Price 5.50 €
• Karapandzic flap for reco...
   Price 10.50 €
• Evaluation of quality of ...
   Price 10.50 €
• Ectopic thyroid basi-ling...
   Price 10.50 €
• Evolution of facial nerve...
   Price 10.50 €
• Endoscopic dacryocystorhi...
   Price 5.50 €
• Voice after supracricoid ...
   Price 10.50 €
• Role of diffusion weighte...
   Price 10.50 €
• The uses of computer-assi...
   Price 10.50 €
• Bullet in the pharynx: En...
   Price 10.50 €
• Nasopharyngeal tuberculos...
   Price 5.50 €
• F0 characteristics in Par...
   Price 12.00 €
• Acute acoustic trauma, a ...
   Price 12.00 €
• Notes on voice and speech...
   Price 8.50 €
• Covering of parotid and c...
   Price 14.00 €
• Endoscopic sphenoid proce...
   Price 8.50 €
• The effect of the speaker...
   Price 10.50 €
• Pre-Congress of the Ameri...
   Price 8.50 €
• Interventional phoniatry...
   Price 14.00 €
• Parapharyngeal lymph node...
   Price 8.50 €
• When to suspect a perilym...
   Price 10.50 €
• PET/CT in the management ...
   Price 10.50 €
• Nasal tumours of the thre...
   Price 10.50 €
• Teratoma of the parotid g...
   Price 5.50 €
• Early evaluation of voice...
   Price 12.00 €
• Formant structures of vow...
   Price 10.50 €
• Malignant mixed tumor of ...
   Price 5.50 €
• BAHA in single sided deaf...
   Price 12.50 €
• Treatment of acute mastoi...
   Price 8.50 €
• Pleomorphic adenoma of th...
   Price 8.50 €
• Air rifle pellet injury t...
   Price 5.50 €
• A survey of current wound...
   Price 5.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• Total pharyngolayngectomy...
   Price 10.50 €
• Vertical extended hemi cr...
   Price 5.50 €

Total Order 324.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 1 - 2005 o

RHINOLOGY

Treatments of hereditary hemorrhagic telangiectasia of the nasal mucosa


Authors : E. Babin, M. Borsik, S. Braccard, L. Crampette, V. Darrouzet, F. Faure, J. P. Fontanel, E. Houdart, R. Jankowski, G. Le Clech, L. Malvezzi, S. Morini, S. Perie, J. Perret, J. C. Pignat, F. Portier, E. Serrano, H. Plauchu (France - Italie)

Ref. : Rev Laryngol Otol Rhinol. 2005;126,1:43-48.

Article published in french
Downloadable PDF document french



Summary : Hereditary Hemorrhagic Telangiectasia is a systemic autosomal dominant disorder involving blood vessels. The most common symptom is reccurent epistaxis. The treatments of these epistaxis are numerous but such treatments are often symptomatic and their effects are often not sustained. Some of these treatments may be complicated by visceral vascular malformations. The aim of this study is to propose a treatment plan for these patients with hierarchical organisation of therapeutic options taking into account of their previous therapy. Method: H. Plauchu organized in Paris, december 2002 a meeting with any medical specialists of this diesease. They have analysed variety of therapies that have been proposed for epistaxis control in Hereditary Haemorrhagic Télangiectasia. Results: Most common use packing of nasal fossa and then hyperselective embolization of the internal maxillary and facial arteries for severe epistaxis. For chronic epistaxis, best treatment use sclerotics products (Ethibloc®) and laser. After discussion, primary embolization could be useful to reduce vascularization of nasal fossa. Conclusion: Treatment of epistaxis in Hereditary Haemorrhagic Telangiectasia could increase in few years. Use of an index card of for epistaxis in the disease of Rendu-Osler could help to find treatment of choice.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE